Factor VIII Level Test in Pakistan at Chughtai Lab

Factor VIII Level at Chughtai Lab

The Factor VIII Level test, also known as the Factor VIII Activity Assay, is a specialized laboratory investigation that measures the activity of Factor VIII, an essential blood-clotting protein. Factor VIII is a key component of the intrinsic pathway of the coagulation cascade. It acts as a cofactor for activated Factor IX (FIXa) to form the tenase complex, which subsequently activates Factor X. This activation is a critical step in the generation of thrombin, the enzyme responsible for converting fibrinogen into fibrin to form a stable blood clot. A deficiency or dysfunction in this protein can lead to severe, uncontrolled bleeding, while abnormally high levels can predispose an individual to pathological blood clots (thrombosis).

At Chughtai Lab, one of Pakistan’s premier diagnostic networks, this test is performed using advanced automated coagulation analyzers that utilize photo-optical or mechanical clot detection systems. The assay is crucial for diagnosing Hemophilia A, an inherited genetic bleeding disorder, and for evaluating patients with unexplained prolonged activated partial thromboplastin time (aPTT). It also plays a vital role in diagnosing von Willebrand disease (vWD), as von Willebrand factor acts as a carrier protein that stabilizes Factor VIII in circulation, protecting it from rapid degradation. Understanding your Factor VIII levels helps hematologists and physicians design targeted treatment plans, monitor therapeutic interventions, and manage bleeding or clotting risks effectively.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the accuracy of the Factor VIII Level test, as physiological factors can significantly influence coagulation protein levels. Patients are advised to adhere to the following guidelines:

• Avoid Strenuous Exercise: Physical exertion, intense workouts, or severe physical stress can cause a transient, significant rise in Factor VIII levels due to the release of adrenaline. Patients should rest quietly for at least 30 minutes before sample collection.
• Medication Disclosure: Inform your physician and the laboratory staff of all medications, supplements, and therapies you are currently undergoing. It is particularly important to report the use of blood thinners (such as heparin, warfarin, or direct oral anticoagulants) and any recent factor replacement therapy, as these can interfere with the assay results.
• Fasting Requirements: Routine fasting is generally not required for a Factor VIII assay. However, if other tests are ordered concurrently on the same blood sample, a fasting period of 8 to 12 hours may be necessary.
• Hydration: Ensure you are well-hydrated by drinking adequate amounts of water before the procedure, as dehydration can affect blood volume and sample quality.

During the Procedure

The Factor VIII Level test requires a standard venipuncture to collect a blood sample. The procedure is conducted by a trained phlebotomist at Chughtai Lab and involves the following steps:

• Sanitization and Preparation: The phlebotomist will identify a suitable vein, typically in the antecubital fossa (inner elbow), and cleanse the area with an antiseptic solution to prevent contamination.
• Tourniquet Application: A tourniquet is applied briefly above the selected site to make the vein more visible and accessible. Prolonged tourniquet application is avoided, as venous stasis can artificially alter coagulation factor levels.
• Sample Collection: A sterile needle is inserted into the vein, and blood is drawn into a light blue-top tube containing 3.2% buffered sodium citrate. This specific anticoagulant binds calcium in the blood, preventing premature clotting and preserving the coagulation factors for laboratory analysis. The tube must be filled completely to ensure the correct 9:1 blood-to-anticoagulant ratio.
• Post-Collection Care: Once the sample is collected, the needle is gently withdrawn, and local pressure is applied to the puncture site with a sterile cotton swab or gauze to stop bleeding. A small bandage is then applied.
• Processing: The blood sample is promptly centrifuged at high speeds to separate the plasma from the cellular components. The resulting platelet-poor plasma is then analyzed using sophisticated coagulometers. The entire blood collection process takes less than five minutes and involves minimal discomfort, similar to a brief pinch.

When is a Factor VIII Level Test Performed?

Diagnosis of Hemophilia A

Hemophilia A is an X-linked recessive genetic disorder characterized by a deficiency or complete absence of Factor VIII. It primarily affects males, while females are typically asymptomatic carriers. Physicians request a Factor VIII Level test when a male infant, child, or adult presents with symptoms of abnormal bleeding, such as spontaneous bleeding into joints (hemarthrosis), deep muscle hematomas, or prolonged bleeding after minor trauma, circumcision, or dental extractions. The test helps confirm the diagnosis and classify the severity of Hemophilia A as mild, moderate, or severe based on the percentage of factor activity present in the blood.

Evaluation of von Willebrand Disease (vWD)

von Willebrand disease is the most common inherited bleeding disorder, caused by a deficiency or dysfunction of von Willebrand factor (vWF). Because vWF serves as the carrier and stabilizer protein for Factor VIII in the bloodstream, a reduction in vWF levels often leads to a secondary, proportional decrease in Factor VIII activity. A Factor VIII Level test is performed alongside vWF antigen and vWF activity assays to comprehensively evaluate patients presenting with mucosal bleeding, frequent nosebleeds (epistaxis), easy bruising, or heavy menstrual bleeding (menorrhagia) to differentiate between hemophilia and various types of von Willebrand disease.

Investigating Unexplained Bleeding or Easy Bruising

When a patient presents with unexplained clinical signs of bleeding, such as frequent, large bruises (ecchymoses) without a history of trauma, prolonged bleeding from minor cuts, or blood in the urine (hematuria) or stool, a coagulation profile is initiated. If the initial screening tests reveal an isolated prolongation of the activated partial thromboplastin time (aPTT) while the prothrombin time (PT) and platelet count remain normal, a specific Factor VIII assay is indicated to pinpoint the exact deficiency within the intrinsic pathway of coagulation.

Monitoring Factor VIII Replacement Therapy

Patients diagnosed with Hemophilia A often receive therapeutic infusions of recombinant or plasma-derived Factor VIII concentrates to prevent or treat bleeding episodes, especially before undergoing surgical or dental procedures. Regular Factor VIII Level testing is performed to monitor the recovery and half-life of the infused factor, ensure therapeutic levels are achieved, and adjust the dosage. It is also used to screen for the development of Factor VIII inhibitors (neutralizing IgG antibodies), which can render replacement therapy ineffective.

Assessing Thrombophilia and Recurrent Blood Clots

While low levels of Factor VIII cause bleeding disorders, persistently elevated levels of Factor VIII are recognized as an independent risk factor for thrombosis (hypercoagulability). Physicians may request this test for patients who have experienced recurrent, unexplained venous thromboembolism (VTE), such as deep vein thrombosis (DVT) or pulmonary embolism (PE), particularly when other common thrombophilic risk factors have been ruled out. Identifying elevated Factor VIII levels helps clinicians assess the long-term risk of recurrence and determine the appropriate duration of anticoagulant therapy.

What Does a Factor VIII Level Test Detect?

The Factor VIII Level test is highly sensitive and can detect a wide range of inherited, acquired, transient, and pathological conditions affecting the coagulation system. Specifically, this assay detects:

• Severe Hemophilia A: Characterized by Factor VIII activity levels of less than 1% of normal, leading to frequent spontaneous joint and muscle bleeds.
• Moderate Hemophilia A: Indicated by Factor VIII levels between 1% and 5% of normal, where bleeding usually occurs after minor trauma.
• Mild Hemophilia A: Indicated by Factor VIII levels between 5% and 40% of normal, where bleeding typically occurs only after major trauma, surgery, or dental extractions.
• Hemophilia A Carrier Status: Female carriers often have Factor VIII levels at the lower end of normal or mildly reduced (typically 40% to 60%), which may occasionally cause mild bleeding symptoms.
• von Willebrand Disease (vWD): Decreased Factor VIII levels resulting from a primary deficiency in von Willebrand factor, which fails to protect Factor VIII from rapid clearance.
• Acquired Factor VIII Inhibitors: The presence of autoantibodies directed against Factor VIII, which can occur in postpartum women, patients with autoimmune diseases (such as systemic lupus erythematosus), or those with certain malignancies, causing severe acquired hemophilia.
• Disseminated Intravascular Coagulation (DIC): An acute, life-threatening condition where widespread activation of coagulation depletes clotting factors, including Factor VIII, leading to simultaneous clotting and severe bleeding.
• Advanced Liver Disease: Although Factor VIII is produced in multiple tissues, severe hepatic failure or cirrhosis can disrupt overall coagulation factor balance and lead to complex coagulopathies.
• Acute Phase Reactant Elevation: Factor VIII is an acute-phase reactant; its levels can rise significantly in response to systemic inflammation, tissue injury, acute infections, or chronic inflammatory diseases.
• Pregnancy-Induced Hypercoagulability: Naturally elevated Factor VIII levels during pregnancy as the body prepares to minimize blood loss during childbirth.
• Estrogen Therapy Effects: Increased Factor VIII activity associated with the use of combined oral contraceptive pills or hormone replacement therapy (HRT).
• Elevated Risk of Deep Vein Thrombosis (DVT): Persistently high Factor VIII levels (above 150%) indicating an increased risk of clot formation in the deep veins of the legs.
• Elevated Risk of Pulmonary Embolism (PE): Increased risk of a blood clot traveling to the lungs, associated with high baseline Factor VIII activity.
• Post-Surgical Transient Elevation: Temporary increase in Factor VIII levels as part of the body’s physiological response to surgical trauma.
• Stress-Induced Fluctuations: Temporary elevations caused by severe physical or emotional stress immediately preceding the blood draw.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing accurate and timely diagnostic services. The turnaround time (TAT) for a Factor VIII Level test is typically within 24 to 48 hours, owing to the specialized nature of coagulation assays which require precise calibration and quality control checks. Once the analysis is completed and verified by a consultant hematologist, patients are notified via SMS. Reports can be easily accessed and downloaded online through the official Chughtai Lab website, the Chughtai Lab mobile application, or via their dedicated WhatsApp self-service portal. Physical copies of the reports can also be collected from any Chughtai Lab collection center across Pakistan.

Factor VIII Level Findings Overview

The following table outlines the clinical interpretation of Factor VIII activity levels and related coagulation parameters:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Factor VIII Activity Level	50% to 150% (0.50 to 1.50 IU/mL)	< 50% (Hemophilia A, vWD, DIC, acquired inhibitors); > 150% (Inflammation, pregnancy, high thrombotic risk)
Activated Partial Thromboplastin Time (aPTT)	25 to 35 seconds	Prolonged (indicates deficiency in intrinsic pathway factors like Factor VIII, IX, XI, XII, or presence of inhibitors)
von Willebrand Factor (vWF) Antigen	50% to 150%	Decreased (suggests von Willebrand Disease, which secondary lowers Factor VIII levels)
Factor VIII Inhibitor Assay (Bethesda Unit)	0 BU (No inhibitor detected)	> 0.5 BU (Indicates presence of neutralizing antibodies/inhibitors against Factor VIII)
Prothrombin Time (PT)	11 to 13.5 seconds	Normal in isolated Factor VIII deficiency; prolonged in liver disease, vitamin K deficiency, or DIC
Platelet Count	150,000 to 450,000 / µL	Normal in Hemophilia A; decreased in DIC, severe liver disease, or associated thrombocytopenia
Fibrinogen Level	200 to 400 mg/dL	Decreased in severe DIC or advanced liver disease; elevated in acute inflammatory states

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Factor VIII Level?

• Experienced Healthcare Professionals: Chughtai Lab employs highly qualified consultant hematologists and pathologists who oversee all coagulation testing and provide accurate clinical interpretations.
• Patient-Focused Care: The laboratory is dedicated to ensuring a comfortable, stress-free experience for patients during sample collection and throughout the diagnostic process.
• Quality Diagnostic Services: Operating under strict internal and external quality control protocols, Chughtai Lab ensures high precision and reliability for specialized hematology assays.
• Professional Reporting: Reports are detailed, structured, and easy for both patients and referring physicians to comprehend, facilitating prompt clinical decision-making.
• Modern Diagnostic Approach: Utilizing state-of-the-art automated coagulation analyzers, the lab minimizes human error and delivers highly reproducible results.
• Comfortable Environment: All collection centers are designed to be clean, hygienic, and welcoming, ensuring patient safety and peace of mind.
• Convenient Location: With an extensive network of diagnostic centers and collection points across major cities in Pakistan, accessing services is highly convenient.
• Commitment to Accurate Diagnosis: Chughtai Lab prioritizes clinical excellence, ensuring that every Factor VIII assay is performed to the highest international standards.